Ac Immune Sa · NASDAQ:ACIU
Ac Immune Sa — Investor Presentation (October 2026)
18 slides from Ac Immune Sa's investor presentation, October 2026
Slide 1: Thumbnails Document Outline Attachments
Thumbnails Document Outline Attachments
Slide 2: Slide index
Slide 1: Investor Presentation Slide 2: Disclaimer Slide 3: AC Immune – targeting the key pathologic misfolded proteins and pathways that drive neurodegenerative diseases Slide 4: Validation from multiple pharmaceutical partners across proprietary platforms and modalities Slide 5: Key milestones 202
Slide 3: Investor Presentation October 2026
Investor NASDAQ: ACIU | Investor Presentation, October 2026© 2026 AC Immune. Not to be used or reproduced without permission PresentationNASDAQ:ACIU|October2026PIONEERING MEDICINE NEURODEGENERATIVE DISEASES NASDAQ: ACIU | Investor Presentation, October 2026© 2026 AC Immune. Not to be used or reprodu
Slide 4: AC Immune – targeting key pathologic misfolded proteins and pathways
NASDAQ: ACIU | Investor Presentation, October 2026© 2026 AC Immune. Not to be used or reproduced without permission Lead program–ACI-7104 targets one of the larges ACImmune–targeting the key path neuroscience with a differentiated approach proteins and pathways that drive neurodegenerative diseases
Slide 5: Key milestones 2026
Active immunotherapiesH1 2026H2 2026ACI-24 (Takeda)Ab NASDAQ: ACIU | Investor Presentation, October 2026© 2026 AC Immune. Not to be used or reproduced without permission dosed in AD4 cohortABATE Phase 2 trial results after 12 months of treatmentACI-7104a-syn2Submissions to regulators regarding clini
Slide 6: Positive Safety & Immunogenicity in Part 1 of VacSYn Phase 2 Trial
NASDAQ: ACIU | Investor Presentation, October 2026© 2026 AC Immune. Not to be used or reproduced without permission6 Exploratory correlation analysis identified trends sugges antibody levels and disease activity measures Exploratory correlationsPrimary endpoints of safety, to met100% of patients dev
Slide 7: Parkinson's disease
NASDAQ: ACIU | Investor Presentation, October 2026© 2026 AC Immune. Not to be used or reproduced without permission Placebo-controlled biomarker-basedPhase2 (clinicaltrials.gov identifier: NCT06015841)(1)Parkinson’s disease (idiopathic);(2)UnifiedParkinson’sdiseaseratingscale25 activeAnalysis▪Primar
Slide 8: Adaptive Phase 2 study of ACI-7104 in early PD
NASDAQ: ACIU | Investor Presentation, October 2026© 2026 AC Immune. Not to be used or reproduced without permission ACI-7104 induces robust ant early PD1 100% responder rate observed for anti-PD012antibody titers in serum 10 ▪All participants exhibited anti-PD01 IgG4antibodies in serum (from week 1
Slide 9: ACI-7104 Phase 2 baseline profile
NASDAQ: ACIU | Investor Presentation, October 2026© 2026 AC Immune. Not to be used or reproduced without permission Exploratory correlation analysis relation to MDS-UPDRS III Correlation of anti-PD01 IgG titersFCBL and MDS-UPDRS Part III C 12 1 ▪While the sample size is small, exploratory analysis s
Slide 10: ACI-7104 induces robust antibody response in early PD
Slide 11: Antibody titers in CSF increase with successive immunizations
Slide 12: Exploratory correlation: antibody titers and MDS-UPDRS III
Slide 13: Summary – ACI-7104 Part 1 results support further development
Slide 14: Adaptive Phase 2 study of ACI-7104 in early PD
Slide 15: Outlook – ACI-7104 moving into expanded Phase 2
Slide 16: ACI-24 for early-stage Alzheimer's disease
Slide 17: Enter the password to open this PDF file. File name:
Enter the password to open this PDF file. Cancel OK File name: -
Slide 18: Title: Author: Subject:
File size: - Title: - Author: - Subject: - Keywords: - Creation Date: - Modification Date: - Creator: - PDF Producer: - PDF Version: - Page Count: - Page Size: - Fast Web View: - Close Preparing document for printing… 0% Cancel Choose File No file chosen